VETERINARYPROGRAM 01 / ANIMAL HEALTH
Canine inflammatory bowel disease
Investigational combination approach targeting the clinical signs associated with canine IBD.
INAD file announced, Oct 2025↗
THE FUTURE OF THERAPEUTIC INNOVATIONVETERINARY FIRST • HUMAN HEALTH POTENTIAL
THE NEXT CHAPTER IN BIOSCIENCE
A new direction in combination therapeutics.
Lupvindol is developing proprietary therapies for inflammatory and autoimmune conditions, with a veterinary-first strategy and a longer-term human pharmaceutical pipeline.
SCIENCE-LED•IP-FOCUSED•DUAL-MARKET STRATEGY
04Therapeutic programs
in the portfolio
in the portfolio
02Veterinary investigational
INAD files announced
INAD files announced
02Target markets
Veterinary + human
Veterinary + human
2025Canine and equine
INAD milestones announced
INAD milestones announced
WHO WE ARE
Rethinking the way we treat inflammation.
Innovation should do more than treat a symptom. It should fundamentally improve the balance between efficacy and tolerability.
Lupvindol is investigating fixed-dose combinations of cannabidiol and corticosteroids for indications where prolonged or repeated conventional treatment may present limitations. Its strategy prioritizes the animal-health pathway while advancing longer-term human applications.
01Focus on meaningful clinical needs
02Novel formulations of established agents
03Development across complementary markets
01 / A DUAL-MARKET PLATFORMDesigned for the next horizon of care.
OUR SCIENTIFIC APPROACH
Two established agents. A new formulation.
The investigational platform combines cannabidiol with corticosteroids in proprietary fixed-dose formulations. The development objective is to achieve effective inflammatory control with lower corticosteroid exposure; outcomes remain subject to study and regulatory review.
THE FORMULATION CONCEPT
ESTABLISHED PHARMACEUTICAL AGENTCorticosteroid
ESTABLISHED PHARMACEUTICAL AGENTCannabidiol
↓
✳
PROPRIETARY DEVELOPMENT PROGRAMInvestigational fixed-dose combinationDesigned to explore a better balance between therapeutic benefit and corticosteroid exposure.
All products and uses described are investigational unless otherwise noted. The site does not claim FDA approval or established clinical efficacy for these combinations.
PORTFOLIO OVERVIEW
One platform. Four possibilities.
Four development programs span veterinary and human medicine. Each represents a distinct indication, development plan and regulatory path.
VETERINARY
VETERINARYPROGRAM 02 / ANIMAL HEALTH
Equine osteoarthritis
Investigational intra-articular combination therapy under veterinary development.
INAD file announced, Oct 2025↗
HUMANPROGRAM 03 / HUMAN HEALTH
Inflammatory bowel disease
Proposed development targeting Crohn's disease and ulcerative colitis.
Human program · Development↗
HUMANPROGRAM 04 / HUMAN HEALTH
Intra-articular joint therapy
Targeted investigational approach for osteoarthritis, subject to clinical development.
Human program · Development↗
Descriptions reflect the company's July 2026 investment memorandum and public announcements; they do not establish clinical effectiveness, regulatory clearance or projected commercialization dates.
OUR STRATEGYAnimal health first.
Broader potential ahead.
Broader potential ahead.
DEVELOPMENT STRATEGY
Built to progress in stages.
Rather than relying on a single clinical outcome, the model is designed around multiple investigational programs and potential partnership pathways.
Nearer-term veterinary development
Advance canine IBD and equine osteoarthritis programs through veterinary research and regulatory milestones, with potential licensing and commercialization opportunities.
01 Veterinarian-led programs
02 Regulatory and development milestones
03 Potential partner-led commercialization
MILESTONES & CATALYSTS
Progress measured in milestones.
Track previously announced regulatory developments and management's forward-looking objectives. Future events are targets, not completed achievements.
13 OCT 2025
PUBLIC ANNOUNCEMENT
Canine IBD INAD opened
Company announcement of an FDA Center for Veterinary Medicine investigational file supporting the canine research program.
Read announcement ↗30 OCT 2025
PUBLIC ANNOUNCEMENT
Equine OA INAD opened
Company announcement of a second veterinary investigational file for its intra-articular equine program.
Read announcement ↗Q4 2026
MANAGEMENT TARGET · NOT VERIFIED
Veterinary regulatory package
The July 2026 memorandum identifies a planned veterinary submission during the fourth quarter of 2026. Current status requires management confirmation.
2027+
FORWARD-LOOKING OBJECTIVES
Human IND progression and partnerships
Potential human regulatory development, manufacturing validation and strategic partnership discussions described in management's roadmap.
INSTITUTIONAL PERSPECTIVE
A disciplined case for possibility.
Four core pillars presented in the company's investment memorandum. These represent the investment thesis, not assurances of future results.
01 / INNOVATION
✳
Scientific innovation
Proprietary combination formulations and a therapeutic objective centered on reduced corticosteroid exposure.
02 / REGULATORY
◇
Regulatory strategy
Programs designed around existing agents and indication-specific regulatory planning.
03 / COMMERCIAL
↗
Veterinary-first model
Exploration of earlier animal-health commercialization opportunities, conditional on development success.
04 / OPTIONALITY
◎
Multiple value pathways
Potential licensing, co-development and asset-level transactions across distinct programs.
OUR LEADERSHIP
The people behind the science.
Multidisciplinary experience across pharmaceutical research, veterinary medicine, clinical care, regulatory affairs, capital markets and law.
THE LUPVINDOL TEAM
Eight specialists. One shared commitment to advancing investigational combination therapeutics.
01 — SCIENTIFIC & EXECUTIVE LEADERSHIP
Hunter Land, PhD
Chief Executive Officer
Read biography
Pharmaceutical R&D leader with over two decades of experience, including cannabinoid science and development work at GW Pharmaceuticals.
02 — BOARD & STRATEGIC LEADERSHIP
Tim Rogers
Chairman
Read biography
Entrepreneur and capital-markets executive experienced in scaling biotechnology ventures and strategic partnerships.
03 — PRECLINICAL RESEARCH
Tim Lefever
Vice President, Research & Development
Read biography
More than 20 years of preclinical research experience, including cannabinoid pharmacology, safety evaluation and translational development.
04 — REGULATORY AFFAIRS
Jennifer L. King, PMP
Director of Regulatory Compliance
Read biography
Regulatory and program-management specialist with more than 25 years of combined experience at the FDA and NIH.
05 — VETERINARY MEDICINE
Trina Hazzah, DVM, DACVIM
Chief Veterinary Officer
Read biography
Veterinary oncologist, researcher and co-founder of the Veterinary Cannabis Society, focused on advancing integrative animal care.
06 — CLINICAL MEDICINE
William Ramsey, DO
Chief Medical Officer
Read biography
Orthopedic surgeon specializing in adult reconstructive surgery, joint preservation and advanced surgical techniques.
07 — FINANCE & GOVERNANCE
Karen Lowe
Chief Financial Officer
Read biography
Chartered Accountant with more than 30 years of experience in finance, risk management, public-market readiness and governance.
08 — LEGAL & SECURITIES
Thomas McCabe, JD
General Counsel
Read biography
Securities attorney with extensive experience in SEC, FINRA and exchange regulatory matters and corporate legal representation.
Leadership roster and portraits sourced from the company's official corporate website.Corporate leadership directory ↗
LEGAL ENTITY DISCLOSURE
Distinct entities. Clear identification.
Investors should review the relevant contracting and issuing entity for each opportunity. The two companies below are separate legal entities; common branding should not be understood as evidence of identical ownership or liabilities.
UNITED STATES ↗
Lupvindol Biosciences Ltd.
Wyoming corporation · United States
2389 Yorktown StreetOceanside, New York 11572Review SEC filing ↗
UNITED KINGDOM ↗
Lupvindol UK Limited
England & Wales · Company No. 12941809
Bretton House, Bell Meadow Business ParkPark Lane, Pulford, Chester CH4 9EPReview Companies House record ↗
FOR QUALIFIED INVESTORS & PARTNERS
See the opportunity in depth.
Request secure access to management materials, diligence documents and program-specific updates. Access is reviewed and granted individually.
◈ Private document vault◈ Authenticator-app verification◈ Controlled investor access
INVESTOR RELATIONS
↗